Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HC-toxin is a naturally occurring cyclic tetrapeptide produced by the plant pathogenic fungus *Cochliobolus carbonum* race 1. It functions as a potent, cell-permeable inhibitor of histone deacetylases (HDACs), enzymes that regulate gene expression by removing acetyl groups from histones. The molecule contains a unique amino acid, 2-amino-9,10-epoxy-8-oxodecanoic acid (Aeo), which features an epoxide group essential for its inhibitory activity; this group covalently and irreversibly binds to the active site of HDAC enzymes. While HC-toxin is primarily known as a critical virulence factor that suppresses plant defense responses in maize, it is extensively utilized in biomedical research as a biochemical tool to study epigenetic regulation, cell cycle progression, and apoptosis in various cancer cell lines.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hc-toxin.